NVDA
NVIDIA
-- 111.180 AVGO
Broadcom
-- 194.390 TSLA
Tesla
-- 263.479 GRRR
Gorilla Technology
-- 28.020 PLTR
Palantir
-- 83.585 
NEWS
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
Monday, 16th December at 8:00 am
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") –
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene Circuit developed by Senti Bio and refers to the chimeric antigen receptor natural killer ("CAR-NK") product candidate manufactured by Celest in China.
Through this collaboration, Celest is leading clinical development, operations and manufacturing of SN301A with technical, strategic and clinical input from Senti Bio. The clinical trial is designed to evaluate safety, pharmacokinetics and preliminary anti-tumor activity of SN301A and will include patients with advanced glypican 3 ("GPC3")-expressing HCC across multiple dose cohorts. The study endpoints include safety assessments for adverse events and dose limiting toxicities, as well as efficacy analyses using standard response criteria for liver cancer.
Monday, 16th December at 8:00 am
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") –
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene Circuit developed by Senti Bio and refers to the chimeric antigen receptor natural killer ("CAR-NK") product candidate manufactured by Celest in China.
Through this collaboration, Celest is leading clinical development, operations and manufacturing of SN301A with technical, strategic and clinical input from Senti Bio. The clinical trial is designed to evaluate safety, pharmacokinetics and preliminary anti-tumor activity of SN301A and will include patients with advanced glypican 3 ("GPC3")-expressing HCC across multiple dose cohorts. The study endpoints include safety assessments for adverse events and dose limiting toxicities, as well as efficacy analyses using standard response criteria for liver cancer.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment